Immix Biopharma, Inc.

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-06-24 13:01:07

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.

feeds.benzinga.com - 2026-06-18 13:38:04

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com - 2026-06-18 10:55:17

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com - 2026-05-27 10:55:16

- Financing includes leading U. S. biotechnology institutional investors and mutual funds - LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.

globenewswire.com - 2026-05-22 17:15:00

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.

globenewswire.com - 2026-05-22 17:15:00

LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close on or about May 22, 2026, subject to the satisfaction of customary closing conditions.

globenewswire.com - 2026-05-21 06:30:00

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  – –   CR rate now 95% (19 of 20 patients)   – –    All CRs reached within 1 year of follow-up post-dosing    – –    No relapses to-date observed for patients who have reached CR    – –    All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month    – –    Next NEXICART-2 Update Expected Late September, 2026    – LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The NEXICART-2 CR rate is now 95% (19 out of 20 patients).

globenewswire.com - 2026-05-21 06:00:00